PTC Therapeutics (PTCT) Earnings Analysis

PTC Therapeutics (PTCT) next reports earnings on 2026-07-30, consensus EPS 0.22 USD. Last quarter (2026-05-07) it beat with EPS -0.03 USD vs -0.45 USD est (+93.3%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -33.59.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PTCT next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.22 USD
Revenue estimate0.30B

PTCT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.03 USD-0.45 USD+93.3%Beat
2026-02-19-1.67 USD-0.21 USD-695.2%Miss
2025-08-07-0.83 USD-1.07 USD+22.4%Beat
2025-02-27-0.24 USD-1.12 USD+78.6%Beat
2024-11-07-1.39 USD-1.54 USD+9.7%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

PTCT valuation and analyst view

Trailing P/E-33.59
Trailing EPS-2.26278 USD
Price / book-35.85
Dividend yield0.00%
Market cap6.46B
Analyst consensusBuy (17 buy / 7 hold / 2 sell)
Avg price target98.5 USD

Related research pages

Frequently asked questions

When is PTC Therapeutics (PTCT)'s next earnings date?

PTC Therapeutics is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.22 USD and revenue estimate of 0.30B.

Did PTCT beat earnings last quarter?

In its 2026-05-07 report, PTCT posted EPS of -0.03 USD versus a -0.45 USD estimate — a beat of 93.3%.

What is PTCT's earnings track record?

Over the last 5 reported quarters with consensus data, PTCT beat estimates 4 times (80%).

What is PTCT's current P/E ratio and EPS?

PTCT trades at a trailing P/E of -33.59 on trailing EPS of -2.2627809643125727 USD.

What do analysts rate PTCT?

Analyst consensus is "Buy" across 26 ratings (0 strong buy, 17 buy, 7 hold, 2 sell, 0 strong sell). Average 12-month price target: 98.5 USD.